In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional ...

Ron Lanton, Partner, Lanton Law, weighs in on the potential international trade, pricing, and access implications of tying US drug costs to those in other developed countries under the Most Favored ...

In the second part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, details what the company’s ...

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

In the first part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, explains how geospatial mapping ...

In the final part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, ...

A cross-sectional study explores how full-benefit dual-eligible beneficiaries differ across MA plans with differing levels of ...

A new observational study finds that people with diabetes taking GLP-1 drugs have a low but doubled risk of developing neovascular age-related macular degeneration, an eye disease that can cause ...

In the first part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, ...

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug ...

Just as importantly, Serialization 2.0 enables better decision-making across the enterprise by unlocking data trapped in ...